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ABSTRACT
Regulation of translation is critical for the accurate
expression of a broad variety of genes that function
in cell cycle progression and cell differentiation, as
well as in the adaptation to cellular stress. The aeti-
ologies of a number of human diseases, including
cancer, have been linked to mutations in genes that
control mRNA translation, or in cis-regulatory mRNA-
sequences. Therefore, research on translational
control and its therapeutic appliance has become
most important. However, to date only a limited
number of therapeutic drugs are known to affect
translational control. Here we describe a novel,
straightforward approach for the detection of cellular
translational activity. We developed a Translational
Control Reporter System (TCRS), which utilizes the
cis-regulatory upstream open reading frame (uORF)
from the c/ebpa locus to direct the translation of a dual
reporter gene into two unique reporter peptides. The
peptides contain a pre-pro-trypsin (PPT) signal for
secretion into the medium and distinct immunogenic
epitopes for detection and quantification purposes.
TCRS-peptide expression levels reflect changes of
translation initiation induced by serum growth fac-
tors, drugs or translation factor mutants. TCRS can
be tailored to various research settings and the sys-
tem may accomplish a broad application to uncover
links between translational control and drugs.
INTRODUCTION
Extra-cellular stimuli, i.e. hormones, growth factors or
nutrients, may induce global changes in protein synthesis.
The translation of subgroups of mRNAs, however, may be
modified differentially. These mRNAs are characterized by
specific translation cis-regulatory elements that allow extra-
cellular stimuli to selectively induce or suppress the expres-
sion of a subset of proteins. Translation cis-regulatory
elements are typically found in transcripts of key regulatory
proteins, e.g. growth factors, cell cycle regulators and
regulators of apoptosis.
In the past decade translational control has been implicated
in various human diseases, highlighting the significance of
this regulatory mechanism (1,2). Some human diseases are
genetically linked to mutations in components of the transla-
tional signalling network, such as Wolcott-Rallison Syndrome
(WRS) (3) and Leucoencephalopathy with vanishing white
matter (VWM) (4), in which mutations affecting the regulation
of translation initiation factor (eIF) 2 have been identified.
Alternatively, mutations in cis-regulatory elements or trans-
lational silencing of target mRNAs may contribute to disease
development, e.g. mutations affecting upstream open reading
frames (uORFs) in the thrombopoietin (TPO) gene causes
hereditary thrombocythaemia (5), and translational silencing
of C/EBPa expression is found in chronic myeloid leukaemia
(CML) (6). In addition, deregulated translation as a result of
disturbed PI3-kinase–PKB/Akt signalling contributes to
tumourigenesis, e.g. in cancer-prone syndromes Cowden,
Chermite-Dudos and Bannayan-Zonana with mutations in
the tumour suppressor PTEN (7). Finally, some drugs that
are believed to act by interfering with translational-control-
signalling, have been applied in the treatment of cancer, or are
in clinical trails, underscoring the therapeutic relevance of
translation control (1,8,9). Albeit the increasing significance
of this approach, the list of translationally active drugs is short.
Therefore, there is an urgent need for research tools that can be
used specifically for the identification and analysis of trans-
lational control processes in the cell.
Initiation of translation is the rate-limiting and the most
regulated step during protein synthesis (10). Small uORFs
have been identified as key cis-regulatory mRNA elements
of translation initiation in a number of regulatory genes,
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including C/EBP (11), SCL/Tal1 (12), ATF-4 (13,14), TPO
(5), CLN3 (15) and BACE-1 (16,17). Several studies have
shown that uORFs function by monitoring the activity
of eIFs (18,19). Thereby they may regulate translation of
the main coding frame per se (20), or translation from altern-
ative downstream initiation sites by ribosome scanning and
re-initiation (Figure 1a). In the latter case, at moderate trans-
lational activity the suboptimal context of the uORF initiation
codon allows part of the ribosomes to read through the uORF
and to initiate translation at the proximal AUG-codon, gener-
ating a long isoform. Poor efficiency of re-initiation at the
distal site further inhibits the expression of the small isoform.
In contrast, at increased translational activity ribosomes may
recognize and translate the uORF, resume scanning and
efficiently re-initiate translation at the distant downstream
AUG-codon, generating a small isoform. Efficiency of re-
initiation at the downstream site depends on reloading with
the ternary eIF2/GTP/Met-tRNAi
Met complex needed for the
re-initiation. In addition, eIF4E as part of the eIF4F-complex
has been shown to stimulate the efficiency of uORF translation
per se and the eIF4F-complex is required for efficient scann-
ing and re-initiation following uORF translation (11,19).
Intriguingly, in this way different proteins with different func-
tions can be expressed from a single mRNA transcript, which
may determine cell-fate as in the case of C/EBPa and b, and
SCL/ Tal1 (11,12).
In order to facilitate the study of mechanisms in trans-
lational control and to exploit translation control in drug
Figure 1. Design and function of the TCRS. (a) General scheme of a functional uORF directing translation from two alternative downstream initiation codons.
The suboptimal context of the uORF initiation codon allows ribosomes to read through the uORF and to initiate translation at the first AUG of the main ORF,
generating a long peptide (LP). In contrast, ribosomes that have translated the uORF resume scanning and may re-initiate translation at the downstream site,
generating a Short Peptide (SP). The efficiency of uORF translation, ribosome re-scanning and translation re-initiation at the distal initiation site depends on
eIF-levels and/ or -activities (b) Schematic representation of the TCRS. TCRS contains three cassettes, a 50 translation regulation cassette with the uORF as the
cis-regulatory element, a peptide expression cassette, and a 30 translation regulation cassette. An LP can be expressed from the peptide expression cassette, containing
N-terminal PPT sequences for secretion, FLAG and HA immuno-epitopes for detection and immobilization purposes, respectively, and eight cysteine residues for
radioactive labelling. Alternatively, an SP can be expressed in a different reading frame (+1), also containing N-terminal PPT sequences, MYC and HA immuno-
epitopes and eight cysteine residues. (c) Transient expression of TCRS- and the control constructs with deleted (D) uORF, LP-expression and SP-expression followed
by immuno-detection in COS-1 cells. Both LP and SP could be detected using anti-HA antibodies. LP and SP could be distinctively detected using anti-FLAG
antibodies and anti-MYC antibodies, respectively. (d) Secretion of TCRS-peptides into the culture medium. LP and SP are secreted into conditioned medium of
TCRS-C33A cell lines. LP and SP were isolated from the medium by immuno-precipitation using anti-HA antibodies against the common HA-epitope and
individually detected by their unique FLAG- and MYC-epitopes, respectively. Asterisk indicates the cross-reacting light chain of the anti-HA antibody employed for
the immuno-precipitation.
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discovery, we have developed an uORF-based Translational
Control Reporter System (TCRS). We show that TCRS rapidly
and efficiently reports changes in the translational activity of
cells exposed to altered growth conditions, translationally
active drugs or mutant translation factors.
MATERIALS AND METHODS
Plasmid construction
The TCRS encoding sequences were prepared by annealing
of synthetic oligonucleotides and PCR, and cloned in pGEM
7Zf(+) (for sequence see Supplementary Figure 1). The final
TCRS constructs were cloned as BamHI–EcoRI fragments
into the expression vectors pSG5 and pcDNA3. Construction
of the human eIF2a-pBabepuro and human eIF4E-pBabepuro
constructs are described in Calkhoven et al. (11).
Cell culture, transfection and retroviral infection
COS-1, C33A, HEK293A and Phoenix E cells (G.P. Nolan,
Stanford University School of Medicine, Stanford, CA;
ATCC, SD 3444) were grown in DMEM supplemented
with 10% fetal calf serum (FCS) in a humidified atmosphere
with 5% CO2 at 37
C. COS-1 cells were transiently transfected
using 5 mg of pSG5 based expression vectors using a DEAE-
Dextran method (21) and harvested 24 h after transfection.
C33A and HEK293A cells were transfected with 5 mg of
pcDNA3-based expression vectors using the calcium phos-
phate DNA precipitation method (22). Pools of cells stably
expressing TCRS were selected for G418-resistance (C33A
0.8 mg/ml; HEK293A 0.7 mg/ml). Upon selection, cells were
maintained in medium supplemented with G418 (0.3 mg/ml).
Ecotropic retroviral packaging Phoenix E cells were transi-
ently transfected with empty pBabepuro, eIF2a-pBabepuro or
eIF4E-pBabepuro constructs using the calcium phosphate DNA
precipitation method, and infectious virus was harvested after
48 h. C33A cells (5 · 105) harbouring TCRS were infected as
described previously (11), selected for puromycin resistance
(2 mg/ml; Sigma) and pooled. Stable TCRS-C33A and TCRS-
HEK293A cells were treated with 1 mM rapamycin (Calbio-
chem), 5 mM 2-aminopurine (2-AP) (Sigma) or 400 nM
Thapsigargin (Calbiochem).
Immune-precipitation
A total of 10 ml culture medium was harvested in siliconized
falcon tubes and immune-precipitated over night with 7 mg
HA11 antibody (MMS-101R, Covance) followed by 2 h
incubation with Protein-G Sepharose-beads (Amersham
Biosciences), rinsed in 5· IP buffer [100 mM NaCl,
50 mM Tris (pH 8) and 0.003% NP40]. The protein was eluted
from the beads with SDS-loading buffer and subsequent
boiling. The entire immune precipitate was used for western
blot analysis, as described below.
Western blot analysis
Cells were harvested in siliconized tubes. Sample prepara-
tion included rapid lysis in 0.5 M NaOH, neutralization
with 0.5 M HCl, addition of SDS-loading buffer, sonication
and boiling. 15% SDS–polyacrylamide gels were used for
protein separation, which were then electro-blotted on a
PVDF membrane (Immobilon-P, Millipore). Western blot
analysis was performed followed by luminescent detection
according to the manufacturer’s instruction (Amersham Life
Technologies, ECL system). For quantification purposes,
western blot analysis was performed and fluorescent dye-
conjugated second antibody (Alexa-Flour 680 goat anti-
mouse antibody) was employed and made visible with the
LI-COR Odyssey Infrared Imaging System according to the
manufacturer’s instruction (LI-COR Biosciences). Quantifica-
tion was directly performed on the blot using the LI-COR
Odyssey Analysis program. Antisera were used at the follow-
ing concentrations: 1:200 eIF2a (C-20) (Santa Cruz Biotech-
nology), 1:200 4E-BP1 (R113) (Santa Cruz Biotechnology),
1:450 mouse anti-FLAG M2 (F 3165) (Sigma), 1:500
anti-eIF4E (610269) (BD Transduction Laboratories),
1:1000 mouse anti-HA11 (MMS-101R) (Covance), 1:1000
anti-Myc (9E10) (Santa Cruz Biotechnology), 1:1000 phos-
pho-eIF2a (Ser51) (Cell Signaling Technology), 1:2000 anti-
goat IgG horseradish peroxidase (HRP) (sc2020) (Santa Cruz
Biotechnology), 1:3000 PKR (M515) (Santa Cruz Biotechno-
logy), 1:5000 ECL anti-mouse IgG HRP (NA931V), 1:5000
ECL anti-rabbit IgG HRP (NA934V), for Odyssey analysis:
1:2500 goat anti-mouse (Alexa-Flour 680).
Enzyme-linked immunosorbent assay (ELISA)
The plates with 96-wells were coated over night using rabbit
anti-HA (1:250) (Novus Biologicals) in a carbonate based
coating buffer (pH 9.6), blocked for 1 h with 10% FCS in
phosphate-buffered saline (PBS), washed with 3· PBS/ 0.05%
Tween and incubated with cell lysates for 2 h. For this purpose
1 · 107 cells were harvested in siliconized tubes, re-suspended
in 400 ml IP buffer, ruptured by sonication and diluted 1:4 to
1:256 in PBS. Upon incubation, the plates were washed three
times with PBS/ 0.05% TWEEN and incubated with mouse
anti-FLAG M2 (F 3165) (1:300) (Sigma) or mouse anti-Myc
(9E10) (1:200) (Santa Cruz Biotechnology) for 1 h, washed
again three times and incubated for 1 h with HRP-linked rabbit
F(ab0)2 anti-mouse IgG (1:3000). For detection purposes, the
plates were rinsed with PBS/ 0.05% Tween and the substrate
solution (BDopt EIA) added according to manufacturer’s
(BD Biosciences) instructions. The reaction was stopped
with 2.5 N H2SO4 and analysed at 450–570 nm.
RESULTS
Design, construction and functioning of the TCRS
TCRS consists of three successive parts (Figure 1b, for
complete sequence see Supplementary Figure 1). The 50-
translation-regulatory-cassette contains the uORF of
C/EBPa, which serves as the cis-regulatory element that con-
trols the site of translation initiation. The peptide expression-
cassette codes for two peptides, one Long Peptide (LP)
expressed from an initiation site proximal to the uORF,
and a Short Peptide (SP) initiated from a site more distal
and in a different reading frame. Finally, the 30-cassette pos-
sesses a polyadenylation (polyA) signal required for efficient
translation.
The peptides contain a common HA-epitope for the immob-
ilization to antibody-coated surfaces, and for detection
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purposes. The specific epitopes, FLAG and MYC in LP and
SP, respectively, serve for the detection and discrimination of
the expressed peptides. In addition, both peptides have eight
cysteine residues for S35-radioactive labelling, to allow
analysis by radioactive-based assays. Both LP and SP start
with N-terminal pre-pro-trypsin (PPT) sequences for targeting
to the endoplasmic reticulum (ER) and secretion. In this way
peptide expression levels may be identified directly in the
culture medium in a convenient way.
To examine the function of TCRS in cell culture, the
TCRS-sequence was cloned into the expression vectors
pSG5 and pcDNA3 and transfected into different cell lines.
The expression of four constructs was analysed by SDS–
PAGE and western-blotting: the complete TCRS with a func-
tional uORF and full coding TCRS-sequence as depicted in
Figure 1b, DTCRS in which the uORF has been rendered
non-functional by a point mutation in the uORF initiation
codon, and control constructs, entirely lacking the 50 regula-
tion cassette and solely coding for either LP or SP. All pep-
tides that contain the HA-epitope could be detected in COS-1
cell extracts by immuno-blotting using anti-HA antibody
(Figure 1c). Staining of the same western blot with anti-
FLAG antibody reveals only the LP, whereas immuno-
staining with anti-MYC antibody selectively identifies the
SP. In addition, both peptides can be detected through their
individual immuno-tags after HA-immuno-precipitation from
conditioned medium of stably TCRS-expressing C33A cells
(Figure 1d) or HEK293A cells (data not shown). Importantly,
elimination of the uORF initiation site in DTCRS results in
expression of the LP only, and abrogates expression of the SP
(Figure 1c and d). Thus similar to the translational regulation
of C/EBPa, b (11) and SCL/Tal1 (12), translation of the SP
is exclusively dependent on an intact uORF in the 50
translational-regulatory-cassette. Hence, the C/EBPa-mRNA
cis-regulatory uORF sequence functions as an independent
translation regulatory unit and can as such be employed in
the TCRS.
TCRS detects changes in regulated translation initiation
induced by serum growth factors or specific drugs
Translation initiation from ordinary initiation AUG-codons as
well as re-initiation at alternative initiation codons following
uORF translation is critically controlled by the initiation
factors eIF2 and eIF4E (11,18). Binding of eIF4E to the
mRNA-cap is a rate-limiting step in the assembly of the
eIF4F-complex. In addition, the eIF4F-complex is essential
for efficient ribosome scanning and re-initiation subsequent
to uORF translation by unknown mechanisms (19). eIF2 deliv-
ers the initiation methionyl-tRNA required for initiation and
re-initiation (23).
An important rationale to design TCRS was to establish
an assay system for the identification of translationally active
compounds. To examine the capacity of TCRS to perform this
task, TCRS-expressing C33A and HEK293A cell lines were
exposed to conditions known to affect translational control and
analysed by quantification of immuno-blotted TCRS-peptides
using fluorescent dye-conjugated secondary antibodies (see
Materials and Methods). Figure 2a shows that serum starva-
tion, which causes suppression of both eIF2 and eIF4E func-
tion and results in the attenuation of translation initiation,
could be followed in the TCRS expression profile as a 3-
fold increase in the LP/SP ratio in the TCRS-HEK293A
cell line.
Attenuation of protein synthesis at the ER by phosphoryla-
tion of eIF2a is a cellular stress response conserved from yeast
to vertebrates (24). Inhibitory binding of the tumour promoting
drug thapsigargin to ER calcium pumps (SERCAs) causes
an ER stress response with rapid activation of ER-bound
eIF2a-kinase PERK, successive phosphorylation of eIF2a
and inhibition of translation initiation (13,25). Figure 1b
shows that inhibition of eIF2 function by 400 nM thapsigargin
resulted in a 3-fold increase of LP/SP ratio after 8 h of
treatment.
Conversely, inhibition of eIF2a-kinases by the potent
ATP-binding site directed inhibitor 2-AP prevents phos-
phorylation of the eIF2a subunit, resulting in activation of
eIF2 function (26) and an increase in translation initiation.
Figure 2c shows that activation of eIF2 function by 5 mM
2-AP was tracked by a gradual 2.5- to 4-fold decrease in the
LP/SP ratio after 8 through 24 h upon treatment in TCRS-
HEK293A cells.
Regulation of eIF4E levels due to inhibitory binding to
hypo-phosphorylated 4E-binding proteins (4E-BPs) is an addi-
tional major and conserved mechanism to control initiation
of translation under various cellular conditions (27). The mam-
malian target of rapamycin (mTOR) stimulates eIF4E-
mediated initiation of translation by maintaining 4E-BPs in
a hyper-phosphorylated and inactive state (28). Rapamycin,
the specific inhibitor of mTOR, and its derivatives have anti-
proliferative activities on tumour cells, and their application
in cancer chemotherapy is currently investigated in several
studies and clinical trials (9,29,30). Figure 2d shows that
1 mM rapamycin reduces the phosphorylation of 4E-BP1
Figure 2. TCRS monitors adjustments in translation initiation induced by drugs, serum or eIF activity. (a) Serum deprivation (0.1% FCS) causes a general attenuation
of translation initiation with hypo-phosphorylation of 4E-BP1 (lower panel), and results in an increase in LP/SP from the TCRS construct (TCRS, upper panel).
Expression of SP was not detected from a related construct lacking the cis-regulatory uORF (DuORF, middle panel). (b) 2-AP (5 mM) inhibits eIF2a-kinases
including PKR, resulting in reduced PKR auto-phosphorylation (lower panel) and hypo-phosphorylation and activation of eIF2a function (lower panels). The
increase in translation resulted in a decrease in LP/SP ratio (TCRS, upper panel). In a related construct devoid of the cis-regulatory uORF, SP-expression was not
detectable (DuORF, middle panel). (c) Thapsigargin (400 nM) causes repression of translation (re-)initiation through hyper-phosphorylation of eIF2a (lower panel),
resulting in an increase in LP/SP ratio (TCRS, upper panel). Expression of SP was not detected from a mutant construct deficient in the cis-regulatory uORF (DuORF,
middle panel). (d) Rapamycin (1mM) inhibits mTOR signalling and attenuates translation through the hypo-phosphorylation of 4E-BP1 (lower panel) and subsequent
sequestering of eIF4E, which results in an increase in LP/SP ratio (TCRS, upper panel). From a mutant construct lacking the cis-regulatory uORF, SP-expression was
not detected (DuORF, middle panel). (e) Expression of the dominant positive mutant eIF2aSA or over-expression of eIF4E increases translation (re-) initiation and
results in enhanced expression of SP relative to LP (TCRS, upper left panel). Expression of SP was not detected from a related construct lacking the cis-regulatory
uORF (DuORF, lower left panel). Control blots show over-expression of eIF2aSA (upper middle for TCRS blot, lower middle forDuORF blot) or eIF4E (upper right
for TCRS blot, lower right for DuORF blot). Experiments were performed in HEK293A (a–d) and C33A (e) cells. Ratios of LP versus SP were measured by
quantification of immuno-blotted TCRS-peptides using fluorescent dye-conjugated secondary anti-HA antibodies. Shown are the mean values of three experiments
with standard deviations (±SD); differences between the ratios are significant (P < 0.05).
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and that the inhibitory effect on translation initiation can be
monitored by an increase in LP/SP ratio in TCRS-HEK293A
cells, up to 2.5-fold. Removing the functional translation cis-
regulatory uORF in TCRS abolishes the expression of SP in all
abovementioned cases (Figure 2a–e, panels labelled with
DuORF).
Taking the data together, changes in translational activity in
vertebrate cells induced by drug-treatment are thoroughly
reported by the TCRS.
Mutant eIF activities are detected by TCRS
Recently mutations in components of the translational
machinery, or aberrant expression of translation factors
have been associated with the aetiology of human diseases
(1). To examine the performance of TCRS in detecting trans-
lational changes caused by aberrant eIF activities, we ectop-
ically overexpressed eIF4E or a dominant positive mutant of
the a-subunit of eIF2 (eIF2a SA) in C33A-TCRS cells by
retroviral transfer of eIF-pBabepuro constructs followed by
selection for puromycin resistance. TCRS expression was ana-
lysed by quantification of immuno-blotted TCRS-peptides
using fluorescent dye-conjugated secondary antibodies (see
Materials and Methods). Enhanced translation initiation as a
consequence of over-expression of eIF4E or a dominant pos-
itive mutant of the a-subunit of eIF2 (eIF2aSA) (31), could be
monitored by a 2-fold decrease in LP/SP ratios (Figure 2e).
Thus translation of the downstream SP-frame is enhanced
when translation re-initiation is improved, which emphasizes
the functionality of the system.
Performance of TCRS in an ELISA setting
To test the suitability of TCRS in an ELISA setting, extracts
from C33A cell lines that contain TCRS or the control
constructs, with deleted (D) uORF, expressing LP only and
expressing SP only, were applied on HA-coated ELISA dishes.
The HA-immobilized LP and SP peptides could be distinct-
ively detected using anti-FLAG and anti-MYC antibodies,
respectively (Figure 3a). Attenuation of translation initiation
in TCRS-expressing HEK293A cells following treatment with
400 nM thapsigargin for 12 h could be detected as a 2-fold
increase in LP/SP ratio measured as a decrease in MYC signal
relative to FLAG signal (Figure 3b). Thus in concordance with
western blot analysis, a shift in the LP/SP ratio can be followed
using TCRS in an ELISA system.
DISCUSSION
Translation control has now been recognized as a crucial
mechanism to regulate the expression of major regulatory
genes involved in cellular functioning, cell cycle progression
and differentiation. Hence it is not surprising that deregulation
of translation is involved in the aetiology of human diseases.
Although the importance of translational control has been
firmly established, the knowledge about the function of
cis-regulatory mRNA elements in conjunction with cellular
signalling and its significance for novel therapeutic concepts is
still limited. Nevertheless, some drugs are known to exert
their effects by interfering with the translation machinery.
Particularly, the drug rapamycin has attracted attention
since it is highly active against a broad range of tumour
cells (9,29).
Here we have presented an efficient method to identify and
analyse changes in translational control in the vertebrate cell
through a TCRS. This system is advantageous in terms of rapid
and easy application and its potential adaptation for high-
throughput screening. In this study the TCRS method is
validated by the detection of changing translational conditions
in the cell, induced by various stimuli: serum growth factors,
drugs and mutant translation initiation factors (eIFs). We
chose the C/EBPa-uORF as the element that controls trans-
lation of the dual reporter gene in TCRS. Previously we
demonstrated that this cis-regulatory element may convert
eIF activity into a translational outcome in its natural setting,
and it functions as an independent cis-regulatory sequence
when separated from its natural sequence context (11). In
addition, the strict conservation of the C/EBPa-uORF
sequence reflects its pivotal role in c/ebpa gene regulation.
Moreover, uORFs with similar functions were identified in
other genes.
Although the uORF mediated translational response is not
understood in all detail, the eIF related effects on TCRS trans-
lation can be explained based on several studies on yeast (18)
and vertebrate genes (11,12,19,32). Our study implies that
probably any alteration in cellular signalling pathways that
affects translation (re-) initiation efficiency through the deliv-
ery of Met-tRNAi
Met by the eIF2-GTP-Met-tRNAi
Met ternary
complex, and/ or through cap-binding and scanning functions
of eIF4E, are rapidly detected by TCRS with a maximum
effect of the readout after 8 h of treatment.
In accordance with the uORF function to monitor cellular
eIF activity and to regulate the alternative use of downstream
initiation codons, enhanced eIF activity results in a relative
increase in translation from the SP initiation site in the
TCRS transcript, reflected in a lower LP/SP ratio. Conversely,
low eIF activity results in a relative decrease in SP levels,
Figure 3. Application of TCRS in an ELISA system. (a) Extracts from C33A
cell lines were applied containing TCRS or the control constructs, with deleted
(D) uORF, expressing LP only, and expressing SP only. LP- and SP-expression
levels were detected through their specific FLAG (black bars) and MYC (grey
bars) immuno-tags following immobilization on HA-coated ELISA dishes. (b)
Thapsigargin-induced down-regulation of translation initiation in HEK293A
cells could be measured in an ELISA setting as an increase in LP/SP ratio
through their specific FLAG (black bars) and MYC (grey bars) immuno-tags,
respectively. The bars represent mean values of duplicate experiments with
standard deviations.
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reflected in higher LP/SP ratios. TCRS was designed to exclus-
ively identify changes in regulated translation: the TCRS read-
out reports differential translational activity through the
expression levels of the two reporter peptides, LP and SP.
Because both reporter peptides are synthesized from a single
transcript it ensures segregation of changes in translation
control from changes due to other regulatory events, such
as transcription-rates or mRNA-stability.
TCRS has a modular design enabling the distinct elements
to be exchanged independently from each other. Foremost,
different (potential) regulatory elements can be cloned into
both the 50- and 30-translation regulation cassettes for exam-
ination. In addition, a construct lacking a functional PPT
leader sequence in LP and SP would allow discrimination
between cytoplasmic-resident translation and translation-
coupled secretion through the ER. The application of TCRS
in ELISA techniques and further development into high-
throughput protocols is tenable by its design with one
immunogenic epitope in common for immobilization and a
distinct second epitope for detection. With the adaptation of
TCRS in transgenic animal models, in vivo studies in trans-
lation control could be performed.
Our work demonstrates that the TCRS is a propitious
method to analyse changes in the translational control status
in the vertebrate cell, and it may be used for the quantification
of a translational response following extra-cellular stimula-
tion. TCRS may become a highly valuable tool in the
development of novel therapeutics to treat human diseases
associated with aberrant translation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors thank Christine Mueller, Jeske J. Smink and Katrin
Zaragoza for discussions, Annett Lassbeck for preliminary
work, and Garry Nolan for Phoenix E cells. This work was
supported by an MDC grant to V.W. and a DFG grant to A.L.
and C.F.C. (LE 770/3-2). Funding to pay the Open Access
publication charges for this article was provided by the
Leibniz Institute of Age Research - Fritz Lipmann Institute,
Jena, Germany.
Conflict of interest statement. None declared.
REFERENCES
1. Calkhoven,C.F., Muller,C. and Leutz,A. (2002) Translational control of
gene expression and disease. Trends Mol. Med., 8, 577–583.
2. Pandolfi,P.P. (2004) Aberrant mRNA translation in cancer pathogenesis:
an old concept revisited comes finally of age. Oncogene, 23,
3134–3137.
3. Delepine,M., Nicolino,M., Barrett,T., Golamaully,M., Lathrop,G.M. and
Julier,C. (2000) EIF2AK3, encoding translation initiation factor
2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome.
Nature Genet., 25, 406–409.
4. Leegwater,P.A., Vermeulen,G., Konst,A.A., Naidu,S., Mulders,J.,
Visser,A., Kersbergen,P., Mobach,D., Fonds,D., van Berkel,C.G. et al.
(2001) Subunits of the translation initiation factor eIF2B are mutant
in leukoencephalopathy with vanishing white matter. Nature Genet.,
29, 383–388.
5. Cazzola,M. and Skoda,R.C. (2000) Translational pathophysiology: a
novel molecular mechanism of human disease. Blood, 95,
3280–3288.
6. Perrotti,D., Cesi,V., Trotta,R., Guerzoni,C., Santilli,G., Campbell,K.,
Iervolino,A., Condorelli,F., Gambacorti-Passerini,C., Caligiuri,M.A.
et al. (2002) BCR-ABL suppresses C/EBPalpha expression through
inhibitory action of hnRNP E2. Nature Genet., 30, 48–58.
7. Di Cristofano,A. and Pandolfi,P.P. (2000) The multiple roles of PTEN in
tumor suppression. Cell, 100, 387–390.
8. Wendel,H.G., De Stanchina,E., Fridman,J.S., Malina,A., Ray,S.,
Kogan,S., Cordon-Cardo,C., Pelletier,J. and Lowe,S.W. (2004) Survival
signalling by Akt and eIF4E in oncogenesis and cancer therapy.
Nature, 428, 332–337.
9. Jundt,F., Raetzel,N., Muller,C., Calkhoven,C.F., Kley,K., Mathas,S.,
Lietz,A., Leutz,A. and Dorken,B. (2005) A rapamycin derivative
(everolimus) controls proliferation through down-regulation of truncated
CCAAT enhancer binding protein beta and NF-kappa B activity in
Hodgkin and anaplastic large cell lymphomas. Blood, 106,
1801–1807.
10. Mathews,M.B., Sonenberg,N. and Hershey,J.W.B. (2000) Origins and
principles of translational control. In Sonenberg,N., Hershey,J.W.B.,
Sonenberg,N. and Mathews,M.B. (ed.) Translational Control of Gene
Expression. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY, pp. 1–31.
11. Calkhoven,C.F., Muller,C. and Leutz,A. (2000) Translational control of
C/EBPalpha and C/EBPbeta isoform expression. Genes Dev., 14,
1920–1932.
12. Calkhoven,C.F., Muller,C., Martin,R., Krosl,G., Pietsch,H., Hoang,T.
and Leutz,A. (2003) Translational control of SCL-isoform expression
in hematopoietic lineage choice. Genes Dev., 17, 959–964.
13. Harding,H.P., Zhang,Y., Bertolotti,A., Zeng,H. and Ron,D. (2000) Perk
is essential for translational regulation and cell survival during the
unfolded protein response. Mol. Cell., 5, 897–904.
14. Vattem,K.M. and Wek,R.C. (2004) Reinitiation involving upstream
ORFs regulates ATF4 mRNA translation in mammalian cells.
Proc. Natl Acad. Sci. USA, 101, 11269–11274.
15. Polymenis,M. and Schmidt,V. (1997) Coupling of cell division to cell
growth by translational control of the G1 cyclin CLN3 in yeast.
Genes Dev., 11, 2522–2531.
16. Rogers,G.W.,Jr, Edelman,G.M. and Mauro,V.P. (2004) Differential
utilization of upstream AUGs in the beta-secretase mRNA suggests
that a shunting mechanism regulates translation. Proc. Natl Acad.
Sci. USA, 101, 2794–2799.
17. De Pietri Tonelli,D., Mihailovich,M., Di Cesare,A., Codazzi,F.,
Grohovaz,F. and Zacchetti,D. (2004) Translational regulation of BACE-1
expression in neuronal and non-neuronal cells. Nucleic Acids Res., 32,
1808–1817.
18. Hinnebusch,A.G. (1994) Translational control of GCN4: an in vivo
barometer of initiation-factor activity. Trends Biochem. Sci., 19,
409–414.
19. Poyry,T.A., Kaminski,A. and Jackson,R.J. (2004) What determines
whether mammalian ribosomes resume scanning after translation of a
short upstream open reading frame? Genes Dev., 18, 62–75.
20. Morris,D.R. and Geballe,A.P. (2000) Upstream open reading
frames as regulators of mRNA translation. Mol. Cell Biol., 20,
8635–8642.
21. Gonzalez,A.L. and Joly,E. (1995) A simple procedure to increase
efficiency of DEAE-dextran transfection of COS cells. Trends Genet.,
11, 216–217.
22. Ausubel,F.M., Brent,R., Kingston,R.E., Moore,D.D., Seidman,J.G.,
Smith,J.A. and Struhl,K. (eds). (2005) Current Protocols in Molecular
Biology. John Wiley & Sons, Vol. 1, Unit 9.1.
23. Dever,T.E. (2002) Gene-specific regulation by general translation factors.
Cell, 108, 545–556.
24. Holcik,M. and Sonenberg,N. (2005) Translational control in stress and
apoptosis. Nature Rev. Mol. Cell Biol., 6, 318–327.
25. Harding,H.P., Zhang,Y. and Ron,D. (1999) Protein translation and
folding are coupled by an endoplasmic-reticulum-resident kinase.
Nature, 397, 271–274.
26. Hu,Y. and Conway,T.W. (1993) 2-Aminopurine inhibits the
double-stranded RNA-dependent protein kinase both in vitro and
in vivo. J. Interferon Res., 13, 323–328.
PAGE 7 OF 8 Nucleic Acids Research, 2006, Vol. 34, No. 3 e23
27. Gingras,A.C., Raught,B. and Sonenberg,N. (1999) eIF4 initiation
factors: effectors of mRNA recruitment to ribosomes and regulators of
translation. Annu. Rev. Biochem., 68, 913–963.
28. Hay,N. and Sonenberg,N. (2004) Upstream and downstream of mTOR.
Genes Dev., 18, 1926–1945.
29. Hidalgo,M. and Rowinsky,E.K. (2000) The rapamycin-sensitive signal
transduction pathway as a target for cancer therapy. Oncogene, 19,
6680–6686.
30. Majewski,M., Korecka,M., Kossev,P., Li,S., Goldman,J., Moore,J.,
Silberstein,L.E., Nowell,P.C., Schuler,W., Shaw,L.M. et al. (2000)
The immunosuppressive macrolide RAD inhibits growth of human
Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo:
a potential approach to prevention and treatment of posttransplant
lymphoproliferative disorders. Proc. Natl Acad. Sci. USA, 97, 4285–4290.
31. Choi,S.Y., Scherer,B.J., Schnier,J., Davies,M.V., Kaufman,R.J. and
Hershey,J.W.B. (1992) Stimulation of protein synthesis in COS cells
transfected with variants of the alpha-subunits of initiation factor
eIF-2. J. Biol. Chem., 267, 286–293.
32. Kozak,M. (2001) Constraints on reinitiation of translation in
mammals. Nucleic Acids Res., 29, 5226–5232.
e23 Nucleic Acids Research, 2006, Vol. 34, No. 3 PAGE 8 OF 8
